Emend Gets Expanded FDA Approval for Preventing PONV
Merck & Co.'s antiemetic Emend (aprepitant) has been granted expanded approval by the FDA to prevent postoperative nausea and vomiting (PONV). Emend, a substance P/neurokinin 1 (NK-1) receptor antagonist, works through a mechanism distinct from that of the 5-HT3 receptor antagonists. Approval was based on two randomized double-blind studies of 1,658 patients undergoing open abdominal surgery. Emend was previously approved for the prevention of chemotherapy-induced nausea and vomiting.
WHITEHOUSE STATION, New JerseyMerck & Co.'s antiemetic Emend (aprepitant) has been granted expanded approval by the FDA to prevent postoperative nausea and vomiting (PONV). Emend, a substance P/neurokinin 1 (NK-1) receptor antagonist, works through a mechanism distinct from that of the 5-HT3 receptor antagonists. Approval was based on two randomized double-blind studies of 1,658 patients undergoing open abdominal surgery. Emend was previously approved for the prevention of chemotherapy-induced nausea and vomiting.
Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology
September 20th 2022Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.
